Remicade biosimilar – Renflexis receives approval from US regulators

US regulators have approved Renflexis, a biosimilar referencing Johnson & Johnson’s tumour necrosis factor (TNF) blocker Remicade (infliximab), across all eligible indications. Physicians will now be able to prescribe the drug for reducing signs and symptoms in patients with adult and paediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and

Continue Reading

Chemists make key advancements to simplify drug design and production

Researchers at Rice University, the University of Texas Southwestern Medical Center and Brigham Young University have discovered a one-step solution to make nitrogen-laden molecular precursors for the preparation of drugs and other bioactive molecules. Research announced this month in Science will simplify the process and cut the cost of creating key nitrogen-containing functional groups for

Continue Reading